Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Bone marrow  (2)
  • HD-Ara-C/DNR consolidation  (2)
  • Antithrombocytic serum  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Identification of young megakaryocytes by immunofluorescence and cytophotometry (1978)
    Springer
    Annals of hematology 37 (1978), S. 265-270 
    Details
    ISSN: 1432-0584
    Keywords: Knochenmark ; Megakaryozytäre Vorläuferzellen ; Megakaryopoese ; Immunfluoreszenz ; Antithrombozytenserum ; Zytophotometrie ; Bone marrow ; Megakaryocytic precursor cells ; Megakaryopoiesis ; Immunofluorescence ; Antithrombocytic serum ; Cytophotometry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The DNA-content of fluoresceine-labeled platelet antigen containing cells of mouse bone marrow was measured. For immunofluorescence highly specific anti-mouse-platelet-serum and fluoresceine-conjugated antigammaglobuline was used, applying the “sandwich” technique. Three hundred panoptically identifiable megakaryocytes served as control group. The DNA-polyploidization pattern of megakaryocytes and immunofluorescence positive cells was almost identical. However, among the immunofluorescence positive cells a considerable amount of cells showed DNA-values lower than 4c, whereas the megakaryocytes of the Pappenheim stained smears revealed no DNA values lower than 4c. The percentages of diploid and tetraploid cells, respectively, was 6 and 7% compared with 0 and 1% of panoptically identifiable megakaryocytes. The results suggest that young megakaryocytic cells with diploid and tetraploid DNA-values can be detected by immunofluorescence technique, indicating that the flow from the uncommited to the committed megakaryocytic precursor cell appears at this early stage of megakaryocyte production.
    Notes: Zusammenfassung Es wurde der DNA-Gehalt von fluoreszeinmarkierten, Thrombozytenantigen enthaltenden Zellen im Knochenmark der Maus untersucht. Die Immunfluoreszenz wurde mit hochspezifischem Anti-Mäuse-Thrombozyten-Serum nach der „sandwich“-Methode mit fluoreszeinkonjugiertem Antigammaglobulin durchgeführt. Als Vergleich dienten 300 nach panoptischen Kriterien differenzierbare Megakaryozyten. Das DNA-Verteilungsmuster der Megakaryozyten und der immunfluoreszenzpositiven Zellen war weitgehend identisch. Allerdings wiesen die immunofluoreszenzpositiven Zellen DNA-Werte auch unterhalb 4c auf, während die im Pappenheim-Präparat differenzierbaren Megakaryozyten keine DNA-Werte in diesem Bereich erkennen ließen. Der Anteil diploder bzw. tetraploider immunfluoreszenzpositiver Zellen betrug 6 bzw. 7% im Vergleich zu 0 bzw. 1% bei den panoptisch differenzierbaren Megakaryozyten. Die Ergebnisse lassen den Schluß zu, daß mit Hilfe der Immunfluoreszenz megakaryozytäre Zellen mit diploidem bzw. tetraploidem DNA-Gehalt nachgewiesen werden können. Dies deutet darauf hin, daß der Einstrom der Zellen aus dem undeterminierten Vorläuferzellkompartment in das determinierte Kompartment bereits auf dieser frühen Stufe der Megakaryozytenproduktion stattfindet.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01539662
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Diploid and tetraploid precursors of megakaryocytes in normal human bone marrow detected by immunofluorescence (1987)
    Springer
    Annals of hematology 55 (1987), S. 459-466 
    Details
    ISSN: 1432-0584
    Keywords: Bone marrow ; Megakarocyte precursor cells ; Immunofluorescence ; Antiplatelet antibody ; Cytophotometry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A sequential preparation method is described which allows immunological identification, morphological characterization, cytophotometric determination of relative DNA content of the megakaryocyte lineage as well as quantitation of megakaryocyte precursors in human bone marrow aspirates. We compared several monoclonal (anti-GP IIIa and HD 19) and polyclonal (A 225, RAHPS) antiplatelet antibodies for immunoflurescent staining. Among the identified cells, a small number of cells showing a diploid and tetraploid DNA content were found which must be regarded as promegakaryoblasts, representing 2.5–4.7% of all megakaryocytes. The heterogenous morphology of these precursors in panoptically stained smears is described.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00367464
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia Long-term follow-up of a prospective multicenter trial (1995)
    Springer
    Annals of hematology 71 (1995), S. 219-225 
    Details
    ISSN: 1432-0584
    Keywords: Key words De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n = 26), were not considered, the median relapse-free-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n = 44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744371
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia (1995)
    Springer
    Annals of hematology 71 (1995), S. 219-225 
    Details
    ISSN: 1432-0584
    Keywords: De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n=26), were not considered, the median relapsefree-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n=44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744371
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...